奥曲肽所致低血糖风险的回顾性研究

目的 探讨奥曲肽引起低血糖风险的危险因素,为临床安全用药提供参考.方法 回顾性分析476例接受奥曲肽治疗的患者的临床资料,对奥曲肽治疗中并发低血糖的相关危险因素进行二元Logistic回归分析.结果 奥曲肽治疗中并发低血糖的发生率为6.51％,发生低血糖组的患者年龄高于未发生组(62.81±13.65)岁vs.(56...

A retrospective study on the risk factors for hypoglycemia caused by octreotide

Objective To investigate the risk factors for hypoglycemia caused by octreotide,and to provide reference for clinical safe medication.Methods The clinical data of 476 patients who received octreotide therapy were collected and analyzed retrospectively.The risk factors associated with hypoglycemia induced by octreotide were identified via Binary Logistic regression analysis.Results The incidence of hypoglycemia induced by octreotide was 6.51%.Patients with hypoglycemia were older(62.81±13.65)years vs.(56.50±15.14)years,P=0.02],and took higher daily dose of octreotide(0.73±0.26)mg/d vs.(0.53±0.30)mg/d,P<0.01].Binary Logistic regression analysis showed that the risk factors associated with hypoglycemia induced by octreotide were age(OR=3.95,95%CI:1.78~8.79,P=0.03),the daily dose of octreotide(OR=4.13,95%CI:1.95~8.74,P<0.01),combined diabetes(OR=2.94,95%CI:1.32~6.53,P<0.01)and using insulin(OR=2.93,95%CI:1.40~6.11,P<0.01).Conclusion The blood glucose level of patients should be monitored when octreotide is used in clinical therapy.The patients should be closely monitored for hypoglycemia especially when the age is over 60,the daily dose of octreotide is more than 0.7 mg,or patients are with diabetes or using insulin.